AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04096781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The participants will receive usual care.
Study NCT02368158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
Description: During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
Study NCT01157962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy in cervical cancer
Description: Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
Study NCT01157962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy in cervical cancer
Description: Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
Study NCT04509024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incidental training
Description: Training involving non-speech sounds embedded in a video-game.
Study NCT04509024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit training
Description: Training involving explicit sound and category information
Study NCT04509024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom training
Description: Structured adult classroom language training.
Study NCT04509024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom and incidental training
Description: Both classroom and incidental training.
Study NCT04509024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom and explicit training
Description: Both classroom and explicit training.
Study NCT03612297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Selective reporting of Antibiotic Susceptibility Tests
Description: Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
Study NCT02532790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1.5mg/kg/d
Study NCT02532790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI
Description: 0.2-0.3mg/kg/d
Study NCT03190161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music session
Description: Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Chirocaine
Description: Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Fentanyl
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group sufentanil
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ephedrine
Description: If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine sulfate
Description: A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate
Description: A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide (10 mg IV) was administered for nausea
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide (10 mg IV) was administered for nausea
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: for severe pruritus
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: for severe pruritus
Study NCT04598100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS-EC
Study NCT05466604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase Injection mesomedica
Description: injection of 150 IU hyaluronidase to perioperative region, submucosally.
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine hydrochloride
Description: pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine hydrochloride
Description: pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac sodium
Description: as additional analgesic among cases in which VAS>3(Postoperatively)
Study NCT01858090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: as additional analgesic among cases in which VAS>3(Postoperatively)
Study NCT03326791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Trombyl 160 mg once daily
Study NCT03326791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo one tablet daily
Study NCT03448822 — intervention group
Intervention type: PROCEDURE
Intervention: sentinel node procedure
Description: a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
Study NCT03876431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy-Flex
Description: The Easy-Flex device will be used to increase knee flexion and extension ROM.
Study NCT03876431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
Study NCT03876431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
Study NCT02670798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastography laboratory testing
Description: Laboratory test that monitors clotting properties of blood
Study NCT02351687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Nutrient Supplement
Study NCT02351687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Study NCT02351687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Study NCT02351687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Study NCT02351687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednet
Study NCT04612842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
Study NCT04211987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast track care protocol
Description: fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
Study NCT04211987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care protocol
Description: standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
Study NCT02088593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Dawn Light Box
Description: per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
Study NCT02088593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene instructions
Description: Sleep Hygiene instructions read aloud
Study NCT05466604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone dekort
Description: injection of 8 mg dexamethasone to perioperative region, submucosally.
Study NCT02088593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene instructions
Description: Sleep Hygiene instructions read aloud
Study NCT01804582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Navigator consultation
Description: Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan.
Study NCT01468610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine
Description: 50-100 mg daily for 8 weeks
Study NCT04634708 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention due to observational design
Study NCT02393846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Description: Topical ketoprofen as used in gel form.
Study NCT02393846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
Study NCT02017366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
Study NCT01959594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-06412562
Description: oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
Study NCT03919513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory pressure threshold device
Description: The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
Study NCT00679146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside+Ketoprofen
Description: 1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
Study NCT00679146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside
Description: 2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
Study NCT01523574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 400mg PO orally
Study NCT01523574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given orally
Study NCT02257177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled TD139
Description: DPI Galectin-3 inhibitor
Study NCT02257177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DPI placebo
Study NCT01980277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301 + paclitaxel
Description: Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
Study NCT01123915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) Low Dose
Study NCT01123915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) Medium dose
Study NCT01123915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) High dose
Study NCT01630551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fishoil supplement
Description: 1 capsule per day
Study NCT01630551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 1 capsule per day
Study NCT02008513 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE® AD02
Study NCT02008513 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03679637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-based aphasia therapy
Description: patients will independently practice with a speech app during hospitalisation
Study NCT02969590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
Study NCT02969590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen and Progesterone Replacement
Description: Replace hormones exogenously to create an artificial cycle
Study NCT03325075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-181388
Description: Escalating dose levels
Study NCT03325075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00869856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 solution for s.c. administration
Description: Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
Study NCT04565717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: ALN-HSD will be administered by subcutaneous (SC) injection.
Study NCT01123915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dimethyl Sulfoxide
Study NCT04565717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
Study NCT03541369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 427
Description: AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
Study NCT01981746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with ropivacaine 0.1%
Description: US-guided adductor canal block
Study NCT02761317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard preparation (2L PEG-ELS)
Description: Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
Study NCT02761317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)
Description: Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
Study NCT02969590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin
Description: Synthetic progestin to assess effects on cervical mucus.
Study NCT02366429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for antenatal depression
Description: Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
Study NCT02366429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual provided at antenatal clinics and other health care instances
Study NCT00529139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard extended dialysis
Description: Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
Study NCT00529139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensified extended dialysis
Description: Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
Study NCT04384380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Description: Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
Study NCT02761317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-volume preparation (4L PEG-ELS)
Description: Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
Study NCT05026372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Compassion (MC)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study NCT04431128 — intervention group
Intervention type: BEHAVIORAL
Intervention: infant feeding position
Description: correlation with allergy, GER or feeding position
Study NCT02773732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 MG
Description: 750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
Study NCT02773732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
Study NCT02773732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 MG
Description: 1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
Study NCT02773732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: 500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
Study NCT00637104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mar-Tyn TiN coated Co-Cr Numen stent implant
Description: Implant of the Mar-tyn TiN coated stent
Study NCT00637104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision Co-Cr stent implant
Description: Implant of the Vision stent
Study NCT02495623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 21 mg
Study NCT02495623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 42 mg